tetano
Editor, Senior Moderator
Clin Exp Med
. 2021 Oct 22;1-11.
doi: 10.1007/s10238-021-00765-1. Online ahead of print.
Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study
Lei Liu[SUP] #[/SUP][SUP] 1 [/SUP], Hang Qu[SUP] 2 [/SUP], Jun Jian Li[SUP] 2 [/SUP], Yan Wei Yang[SUP] 2 [/SUP], Qiu Xi Zeng[SUP] #[/SUP][SUP] 3 [/SUP], Yan Wen Gong[SUP] 3 [/SUP], Zhong Zhi He[SUP] 3 [/SUP], Yi He Zhang[SUP] 3 [/SUP], Wei Zhang[SUP] 3 [/SUP], Bin Liu[SUP] 2 [/SUP], Li Chun Che[SUP] 4 [/SUP]
Affiliations
Abstract
The optimal timing of glucocorticoid treatment for coronavirus disease 2019 (COVID-19) pneumonia is uncertain. We evaluated the clinical outcomes of methylprednisolone therapy (MPT) for patients with a high-risk common type (HRCT) COVID-19 pneumonia. We conducted a multicenter retrospective cohort study in Northeast China. A comparison was performed between the standard treatment (SDT) group and the SDT + MPT group to determine the efficacy of methylprednisolone in treating HRCT COVID-19 pneumonia. We collected the medical records of 403 patients with HRCT COVID-19 pneumonia (127 in the SDT + MPT group and 276 in the SDT group). None of the patients had received mechanical ventilation or died. Furthermore, there were no side effects associated with MPT. Patients in the SDT + MPT group treated with methylprednisolone received an intravenous injection for a median interval of five days (interquartile range of 3 to 7 days). The trends in lymphocyte count, C-reactive protein, interleukin 6, lactic acid dehydrogenase, respiratory rate, SpO2, PaO2, D-dimer and body temperature were similar between the SDT + MPT and SDT groups. The results for the SDT + MPT group seemed to improve faster than those for the SDT group; however, the results were not statistically significant. Clinical outcomes revealed that the average hospitalized days and the rate of progression to severe type COVID-19 pneumonia in both the SDT + MPT group and the SDT group were 14.56 ± 0.57 days versus 16.55 ± 0.3 days (p = 0.0009) and 21.26% (27/127) versus 32.4% (89/276) (p = 0.0247), respectively. The 16-day nucleic acid negative rate was higher in the SDT + MPT group than in the SDT group, 81.73% (104/127) versus 65.27% (180/276) (p = 0.0006). MPT effectively prevents patients with HRCT COVID-19 pneumonia from progressing to the severe stage.
Keywords: A high-risk common type; COVID-19 pneumonia; Methylprednisolone therapy; Optimal timing.
. 2021 Oct 22;1-11.
doi: 10.1007/s10238-021-00765-1. Online ahead of print.
Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study
Lei Liu[SUP] #[/SUP][SUP] 1 [/SUP], Hang Qu[SUP] 2 [/SUP], Jun Jian Li[SUP] 2 [/SUP], Yan Wei Yang[SUP] 2 [/SUP], Qiu Xi Zeng[SUP] #[/SUP][SUP] 3 [/SUP], Yan Wen Gong[SUP] 3 [/SUP], Zhong Zhi He[SUP] 3 [/SUP], Yi He Zhang[SUP] 3 [/SUP], Wei Zhang[SUP] 3 [/SUP], Bin Liu[SUP] 2 [/SUP], Li Chun Che[SUP] 4 [/SUP]
Affiliations
- PMID: 34677701
- PMCID: PMC8532093
- DOI: 10.1007/s10238-021-00765-1
Abstract
The optimal timing of glucocorticoid treatment for coronavirus disease 2019 (COVID-19) pneumonia is uncertain. We evaluated the clinical outcomes of methylprednisolone therapy (MPT) for patients with a high-risk common type (HRCT) COVID-19 pneumonia. We conducted a multicenter retrospective cohort study in Northeast China. A comparison was performed between the standard treatment (SDT) group and the SDT + MPT group to determine the efficacy of methylprednisolone in treating HRCT COVID-19 pneumonia. We collected the medical records of 403 patients with HRCT COVID-19 pneumonia (127 in the SDT + MPT group and 276 in the SDT group). None of the patients had received mechanical ventilation or died. Furthermore, there were no side effects associated with MPT. Patients in the SDT + MPT group treated with methylprednisolone received an intravenous injection for a median interval of five days (interquartile range of 3 to 7 days). The trends in lymphocyte count, C-reactive protein, interleukin 6, lactic acid dehydrogenase, respiratory rate, SpO2, PaO2, D-dimer and body temperature were similar between the SDT + MPT and SDT groups. The results for the SDT + MPT group seemed to improve faster than those for the SDT group; however, the results were not statistically significant. Clinical outcomes revealed that the average hospitalized days and the rate of progression to severe type COVID-19 pneumonia in both the SDT + MPT group and the SDT group were 14.56 ± 0.57 days versus 16.55 ± 0.3 days (p = 0.0009) and 21.26% (27/127) versus 32.4% (89/276) (p = 0.0247), respectively. The 16-day nucleic acid negative rate was higher in the SDT + MPT group than in the SDT group, 81.73% (104/127) versus 65.27% (180/276) (p = 0.0006). MPT effectively prevents patients with HRCT COVID-19 pneumonia from progressing to the severe stage.
Keywords: A high-risk common type; COVID-19 pneumonia; Methylprednisolone therapy; Optimal timing.